Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
A malleable polysaccharide soft tissue filler for filling tissue cavities or voids such as those resulting from tumor removal or other tissue resection. The soft tissue filler includes a first cross-linking polysaccharide, preferably a beta-D glucan and a second cross-linking polysaccharide. The soft tissue filler is both porous and malleable and can be formed to accommodate the tissue cavity or void. The soft tissue filler can include an embedded marker for locating on medical imaging. Methods of making the soft tissue filler including lyophilizing an aqueous polysaccharide suspension are disclosed. The second cross-linking polysaccharide provides for increased structural integrity in a high-porosity and malleable soft tissue filler in which the respective cross-linking polysaccharides synergistically provide structural scaffolding for one another. Methods of use are also disclosed.
Core Innovation
The invention provides a malleable soft tissue filler for use to fill a body cavity in a mammal in which soft tissue has been removed to create the body cavity. The filler is made from a low-content first cross-linking polysaccharide material that is (1-3), (1-4) beta-D-glucan and a small amount of a second cross-linking polysaccharide material that is agarose. An aqueous suspension of both polysaccharides is formed and then lyophilized to create a porous open-cell scaffold.
The porous matrix is described as having improved structural integrity and malleability compared to using glucan alone, enabling the filler to be user shaped and to support tissue ingrowth. The lyophilization of the aqueous suspension is described as producing a porous scaffold, where the step of lyophilizing includes first freezing and then desiccating to make the malleable soft tissue filler.
The invention further describes that the filler can be formulated using defined weight-percent ranges for the first and second cross-linking polysaccharide materials and a density range of about 5.0 to about 300 mg/cc. The porous filler can optionally include embedded or adjacent imaging or fiducial markers that are visible on kV X-ray, CT, CBCT, mammography, ultrasound, and MRI, and example marker types described include pyrolytic carbon-coated ceramic and BiomarC® Enhanced Fiducial Marker.
Claims Coverage
The independent claims cover making, using, and composition of a malleable soft tissue filler based on an aqueous suspension of (1-3), (1-4) beta-D-glucan and agarose followed by lyophilization, with a use method involving insertion into a body cavity and closure, and a product claim specifying composition ranges and density.
Polysaccharide aqueous suspension and lyophilization for malleable soft tissue filler
Creating a mixture by mixing about 0.5 percent by weight to about 2 percent by weight of a first cross-linking polysaccharide material with water and from about 0.01 percent by weight to about 0.3 percent by weight of a second cross-linking polysaccharide material with water for a sufficient time to form an aqueous suspension of both the first cross-linking polysaccharide material and the second cross-linking polysaccharide material, wherein the first cross-linking polysaccharide material is (1-3), (1-4) beta-D-glucan and wherein the second cross-linking polysaccharide material is agarose, and lyophilizing the aqueous suspension.
Two cross-linking polysaccharide aqueous suspension lyophilization
Lyophilizing an aqueous suspension made by forming a mixture by mixing from about 0.5 percent by weight to about 2 percent by weight of a first cross-linking polysaccharide material and from about 0.01 percent by weight to about 0.3 percent by weight of a second cross-linking polysaccharide material with water for a sufficient time to form an aqueous suspension of both the first cross-linking polysaccharide material and the second cross-linking polysaccharide material, wherein the first cross-linking polysaccharide material is (1-3), (1-4) and wherein the second cross-linking polysaccharide material is agarose.
Malleable soft tissue filler preparation via lyophilizing aqueous suspension and use by insertion and closure
Providing a malleable soft tissue filler by lyophilizing an aqueous suspension made by creating a mixture by mixing from about 0.5 percent by weight to about 2.0 percent by weight of a first cross-linking polysaccharide material and from about 0.01 percent by weight to about 0.3 percent by weight of a second cross-linking polysaccharide material with water for a sufficient time to form an aqueous suspension of both the first cross-linking polysaccharide material and the second cross-linking polysaccharide material, wherein the first cross-linking polysaccharide material is (1-3), (1-4) beta-D-glucan and the second cross-linking polysaccharide material is agarose, wherein the step of lyophilizing the aqueous suspension includes first freezing the aqueous suspension to form a frozen aqueous suspension and then desiccating the frozen aqueous suspension to make the malleable soft tissue filler, inserting the malleable soft tissue filler into the body cavity, and closing the body cavity.
Malleable soft tissue filler composition from beta-D-glucan and agarose with specified density
Comprising from about 50.0 to about 99.9 percent by weight of a first cross-linking polysaccharide material and from about 0.03 percent by weight to about 50.0 percent by weight of a second cross-linking polysaccharide material, wherein the density of the malleable soft tissue filler is from about 5.0 to about 300 mg/cubic centimeters (mg/cc), wherein the first cross-linking polysaccharide material is (1-3), (1-4) beta-D-glucan and the second cross-linking polysaccharide material is agarose.
Across the independent claims, the core coverage is a malleable soft tissue filler and methods based on an aqueous suspension containing (1-3), (1-4) beta-D-glucan and agarose followed by lyophilization, plus a use method involving insertion into a body cavity and closure, and a product claim specifying composition ranges and a density range.
Stated Advantages
Improved structural integrity and malleability versus glucan alone.
Enables user shaping.
Supports tissue ingrowth.
Documented Applications
Filling lumpectomy or tumor resection cavities (body cavities created after soft tissue removal) in a mammal following surgical removal of soft tissue.
Use in closing the body cavity after inserting the malleable soft tissue filler.
Interested in licensing this patent?